• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 5. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890

Research Brief on 3-(but-3-en-2-yl)-1-(1-hydroxypropan-2-yl)thiourea (CAS: 2168626-52-4): Recent Advances and Applications

In recent years, the compound 3-(but-3-en-2-yl)-1-(1-hydroxypropan-2-yl)thiourea (CAS: 2168626-52-4) has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential use in drug development. The following sections provide a comprehensive overview of the current state of research, highlighting key methodologies, results, and implications for future studies.

The compound 3-(but-3-en-2-yl)-1-(1-hydroxypropan-2-yl)thiourea belongs to the thiourea derivative family, which is known for its diverse biological activities, including antimicrobial, antifungal, and anticancer properties. Recent studies have explored its potential as a scaffold for designing novel inhibitors targeting specific enzymes or pathways. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in inhibiting the activity of certain kinases involved in inflammatory responses, suggesting its potential as an anti-inflammatory agent.

One of the key challenges in working with this compound has been optimizing its synthesis to improve yield and purity. A recent breakthrough in synthetic methodology, reported in Organic Letters (2024), describes a streamlined two-step process that significantly enhances the scalability of production. This advancement is expected to facilitate further pharmacological evaluations and preclinical studies, paving the way for its potential application in drug discovery pipelines.

In addition to its synthetic and biological properties, computational studies have also shed light on the molecular interactions of 3-(but-3-en-2-yl)-1-(1-hydroxypropan-2-yl)thiourea with target proteins. Molecular docking simulations, as detailed in a 2024 Bioorganic Chemistry article, revealed high binding affinity to specific active sites, corroborating experimental findings and providing a structural basis for its inhibitory effects. These insights are invaluable for rational drug design and the development of more potent analogs.

Despite these promising developments, several questions remain unanswered. For example, the compound's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME) properties, requires further investigation. Preliminary in vivo studies, as reported in a recent preprint, indicate moderate bioavailability but highlight the need for formulation optimization to enhance its therapeutic potential. Future research should also explore its safety profile and potential off-target effects to ensure its suitability for clinical applications.

In conclusion, 3-(but-3-en-2-yl)-1-(1-hydroxypropan-2-yl)thiourea (CAS: 2168626-52-4) represents a promising candidate for further exploration in medicinal chemistry. Its versatile biological activities, coupled with recent advancements in synthesis and computational modeling, position it as a valuable scaffold for drug development. Continued research efforts should focus on addressing existing gaps in knowledge, particularly in ADME and toxicology, to unlock its full therapeutic potential. This brief underscores the importance of interdisciplinary collaboration in advancing the understanding and application of this compound in the chemical biology and pharmaceutical fields.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)